Home > Pressrelease > Stem Cell Therapy Market size to exceed $31.5Bn by 2032

Stem Cell Therapy Market size to exceed $31.5Bn by 2032

  • Published Date: February 23, 2023

Stem Cell Therapy Market size is anticipated to reach USD 31.5 billion by 2032, as per a new research report announced by Global Market Insights Inc.

Growing R&D initiatives by companies involved in stem cell therapies and products are a key driver behind market expansion. The growing availability of upgraded stem cell therapies over the recent can be attributed to intense R&D efforts. Many firms are now redirecting their focus towards enhancing the effectiveness of stem cell therapies, outlining the industry scenario in a more well-defined manner. In January 2023, for instance, DiscGenics Inc., a clinical-stage biopharmaceutical company, unveiled positive two-year clinical data from its first-ever IDCT clinical research in humans for lumbar degenerative disc disease.

Allogenic stem cell therapies to report elevated demand fueled by their easy scalability

Driven by its easy scalability, which increases accessibility, the allogenic stem cell therapy segment is likely to come up as a sizable revenue pocket for the stem cell therapy market. Allogenic stem cell therapies have numerous benefits over their autologous counterparts. In such therapies, the derivation of stem cells from young healthy donors eliminates any co-morbidities in disease states. In addition, the donor stem cells form their immune cells, which help kill any cancer cells present after a heavy dose of treatment.

Furthermore, this therapy does not impair the immune system and is safely used in humans. The allogenic stem cells do not contain tumor-contaminating cells, eliminating the chances of reoccurrence of the disease. In labs, these cells can be modified for a multitude of applications. The growing reliance on allogenic regenerative therapies is stimulating segment progress.

Browse key industry insights spread across 120 pages with 227 market data tables & 14 figures & charts from the report,  “Stem Cell Therapy Market Size by Type (Allogenic Stem Cell Therapy, Autologous Stem Cell Therapy), By Therapeutic Area (Oncology, Orthopedic, Cardiovascular, Neurology), End-use (Hospitals, Clinics), COVID-19 Impact Analysis, Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2023 – 2032 in detail along with the table of contents:

Rising prevalence of cardiovascular disorders to foster therapeutic area segment

Stem cell therapy market revenue from cardiovascular segment is likely to hit USD 7.9 billion by 2032, fueled primarily by the growing prevalence of cardiovascular diseases (CVDs) across the globe. The trophic mediators secreted by stem cells reduce inflammation, attenuate tissue injury, and inhibit fibrotic remodeling, improving cardiac function. Many clinical trials have also proved the efficacy of cell-based therapies in improving cardiac functioning.

By promoting the regeneration of damaged myocardium, these therapies have the potential to transform the traditional methods of CVD treatment. New research has also created scope for cellular therapies for preventing CVDs, further bolstering the segment scenario.

Favorable government efforts to strengthen Asia Pacific stem cell therapy industry

Asia Pacific stem cell therapy market share is poised to grow at CAGR of 10.5% by 2032, owing to recent government-funded scientific research efforts that have accelerated the development of advanced stem cell therapies in economies such as India, China, and Japan among others. In fact, the Government of India recently invested towards basic and clinical stem cell research initiatives through various departments with the help of national funding agencies like the Department of Biotechnology (DBT), Department of Science and Technology (DST), and Indian Council of Medical Research (ICMR).

The government of China has also invested the majority of its science funding towards stem cell research. Meanwhile, government efforts are also being put towards popularizing stem cell therapies in the region. Many nations have set-up a favorable regulatory environment for the market, nurturing novel stem cell therapies in the region. The surging awareness brought about by these efforts is slated to translate into notable growth when combined with the growing burden of chronic ailments in APAC.

Product innovations to define the competitive landscape for stem cell therapy market

The list of leading stem cell therapy industry players includes names such as ThermoGenesis Holdings, Inc., Mesoblast Ltd., MEDIPOST Co., Ltd., GSK plc., and DiscGenics, among others.

Authors: Sumant Ugalmugle, Subodh Kharad